MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase.
Heparanase (HPSE) is a potent protumorigenic, proangiogenic, and prometastatic enzyme that is overexpressed in brain metastatic breast cancer (BMBC). However, little is known about the regulation of this potential therapeutic target in BMBC, which remains very poorly managed in the clinic. We hypothesized that HPSE gene expression might be regulated by micro RNA that might be exploited therapeutically. Using miRanda and RNAhybrid, we identified miR-1258 as a candidate micro RNA that may directly target HPSE and suppress BMBC. In support of our hypothesis, we found that miR-1258 levels inversely correlated with heparanase expression, enzymatic activity, and cancer cell metastatic propensities, being lowest in highly aggressive BMBC cell variants compared with either nontumorigenic or nonmetastatic human mammary epithelial cells. These findings were validated by analyses of miR-1258 and heparanase content in paired clinical specimens of normal mammary gland versus invasive ductal carcinoma, and primary breast cancer versus BMBC. In regulatory experiments, miR-1258 inhibited the expression and activity of heparanase in BMBC cells, whereas modulating heparanase blocked the phenotypic effects of miR-1258. In functional experiments, stable expression of miR-1258 in BMBC cells inhibited heparanase in vitro cell invasion and experimental brain metastasis. Together, our findings illustrate how micro RNA mechanisms are linked to brain metastatic breast cancer through heparanase control, and they offer a strong rationale to develop heparanase-based therapeutics for treatment of cancer patients with brain metastases, BMBC in particular.
Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.
Lixin
L
Zhang
Peggy S
PS
Sullivan
Jerry C
JC
Goodman
Preethi H
PH
Gunaratne
Dario
D
Marchetti
D000818:Animals; D001932:Brain Neoplasms / Q000201:enzymology / Q000235:genetics / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D015536:Down-Regulation; D005260:Female; D015316:Genetic Therapy; D005966:Glucuronidase / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000008:administration & dosage* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D014162:Transfection; D023041:Xenograft Model Antitumor Assays; D000099175:Heparanase
D005966:Glucuronidase; D035683:MicroRNAs; D000099175:Heparanase; C576996:MIRN1258 microRNA, human
RNA. 2004 Oct;10(10):1507-17
15383676
J Cell Biochem. 2006 Feb 1;97(2):217-25
16288472
Cancer Res. 2000 Sep 1;60(17):4767-70
10987284
Adv Enzyme Regul. 2001;41:343-59
11384754
Cancer Res. 2008 Dec 15;68(24):10077-85
19074873
Nat Methods. 2006 Jan;3(1):27-9
16369549
Int J Biochem Cell Biol. 2006;38(12):2018-39
16901744
Int J Mol Med. 2006 Feb;17(2):221-8
16391819
Cell. 2009 Jun 12;137(6):1032-46
19524507
Mol Cancer Res. 2010 Feb;8(2):278-90
20164500
Cancer Res. 2010 Mar 1;70(5):1906-15
20179198
N Engl J Med. 2005 Oct 27;353(17):1768-71
16251533
J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30
15316057
Clin Exp Metastasis. 2004;21(2):107-18
15168728
PLoS One. 2009;4(4):e5181
19360105
Int J Cancer. 2006 Apr 1;118(7):1609-17
16217746
J Microsc. 2005 Mar;217(Pt 3):275-81
15725131
Clin Cancer Res. 2007 Mar 15;13(6):1656-62
17363518
Nature. 2008 Jan 10;451(7175):147-52
18185580
Cancer Res. 2010 Jan 1;70(1):378-87
19996288